China Dodges Chance To Impose Linkage And Exclusivity
Patent-linkage and data exclusivity changes have not been implemented in a major overhaul of medicines law in China. But they could still come through patent law updates.
You may also be interested in...
Much anticipated legislation signals flexibility over online sales of pharma products and definition of counterfeits, but the law also falls short on key elements of pharmaceutical innovation and intellectual property rights protection, says one legal expert.
China's National Health Commission issues list of 34 generic drugs that have 'insufficient' competition, seeking public comments.
By sharing 80% of its tender contracts to multiple suppliers, German insurance fund Barmer is aiming to mitigate the risk of medicines shortages.